



(51) International Patent Classification:

G01N 33/564 (2006.01) A61P 25/24 (2006.01)
A61K 39/00 (2006.01) A61P 25/28 (2006.01)
A61P 25/00 (2006.01) C07K 16/28 (2006.01)
A61P 25/08 (2006.01) G01N 33/68 (2006.01)
A61P 25/18 (2006.01)

(21) International Application Number:

PCT/US2024/022024

(22) International Filing Date:

28 March 2024 (28.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/493,217 30 March 2023 (30.03.2023) US

(71) Applicant: ARIALYS THERAPEUTICS, INC.

[US/US]; 11099 N Torrey Pines Road, Suite 290, La Jolla,
California 92037 (US).

(72) Inventors: MATSUMOTO, Mitsuyuki; 11099 N Torrey
Pines Road, Suite 290, La Jolla, California 92037 (US). YA-
MAKI, Shanni; 11099 N Torrey Pines Road, Suite 290, La
Jolla, California 92037 (US). KAZAMI, Roghiye; 11099
N Torrey Pines Road, Suite 290, La Jolla, California 92037
(US). RAZAI, Amir; 11099 N Torrey Pines Road, Suite
290, La Jolla, California 92037 (US). EASTMAN, Vallari;
11099 N Torrey Pines Road, Suite 290, La Jolla, California
92037 (US). SNIPAS, Scott; 11099 N Torrey Pines Road,
Suite 290, La Jolla, California 92037 (US).


(74) Agent: CHEN, Yijing et al.; Wilson Sonsini Goodrich &
Rosati, 650 Page Mill Road, Palo Alto, California 94304
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

(54) Title: DETECTION OF AUTOANTIBODIES AGAINST NR1

FIG. 8A

10% Serum



(57) Abstract: The disclosure provides systems and methods for detecting anti-NMDAR autoantibody based on the strong affinity of anti-NMDAR autoantibodies to a plurality of non-randomized anti-NR1 coupled to a solid support. The disclosure further provides therapeutic methods for an anti-NMDAR pathology by a therapeutic anti-NMDAR antibody, ART5803. The disclosure further provides methods and systems for screening and predicting the potential responsiveness to ART5803 treatment.

[Continued on next page]

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*